Hepatitis B Core-Related Antigen
A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Human Virology and Viral Diseases".
Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 2504
Special Issue Editor
Special Issue Information
Dear Colleagues,
Hepatitis B virus (HBV) infection remains a global health problem, with estimated 257 million people being chronically infected and at high risk of developing severe liver diseases, such as fibrosis, cirrhosis and hepatocellular. Current therapies can efficiently supress virus replication and slow down disease progression, but cannot completely cure HBV infection due to the persistence of covalently closed circular DNA (cccDNA) in the nucleus of infected hepatocytes. Efforts to develop novel antivirals and to identify new biomarkers to monitor the viral activity, especially the level and activity of cccDNA, are needed to benefit the treatment of chronic hepatitis B patients.
The hepatitis B core-related antigen (HBcrAg) is defined as a composite antigen, including HBV core antigen (HBc), e antigen (HBeAg) and the precore-related antigen (PreC, also known as p22cr), which have been reported to be detected in the sera of HBV infected patients. Of the HBcrAg mixture, the classic HBc serves as the viral structural protein to form HBV capsid and also plays regulatory roles in HBV replication and potentially in pathogenesis, and thus has emerged as new target of antivirals like core allosteric modulators (CAMs). HBeAg, as the major component of HBcrAg in HBeAg-positive patients, is thought dispensable for HBV replication but playing important roles in modulating the host immune response and is clinically used as a marker reflecting HBV replication level. Recently, HBcrAg has been widely studied in monitoring intrahepatic cccDNA and predicting outcomes of antiviral therapies and is regarded as one potential biomarker of HBV infection and activity. However, there are still some knowledge gaps and debates in the characteristics, biological functions and detections of HBcrAg, which limits the application of HBcrAg as a serological biomarker.
In this Special Issue, we aim for research and review articles that could contribute to improving our understanding of the characteristics of HBcrAg, the roles and exact mechanisms of HBcrAg or individual components of HBcrAg in HBV replication and in HBV-host immune system interaction and thus pathogenesis. We particularly look forward to studies that focus on the accurate detection and analysis of HBcrAg and/or each HBcrAg component during HBV infection and treatment and the roles of HBcrAg and/or individual components in monitoring HBV activity, especially intrahepatic cccDNA activity, and in predicting the treatment responses and disease progression of chronic hepatitis B.
Dr. Kuancheng Liu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hepatitis B virus
- core-related antigen
- HBcrAg
- HBc
- HBeAg
- PreC
- biomarker
- cccDNA activity
- pathogenesis
- disease progression
